Exemestane may be another first-line, adjuvant therapy for hormone-receptor positive, early-stage breast cancer

Thursday, December 9, 2010 - 12:02 in Health & Medicine

Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.

Read the whole article on Physorg

More from Physorg

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net